High-throughput dia-PASEF workflow improves proteome coverage and

quantitative performance in repeated-measures proteomics of cervicovaginal fluid

within a preconception cohort

Mauricio Hernandez[1,3]†, Pablo Saldivia[1,2]†, Veronica Latapiat[1]†, Barbara Antilef[1], Guillermo

Nourdin[1], Felipe Castro[1], Cristian Vargas[1], Elard S. Koch[1]*.

1 MELISA Institute, Dalcahue 1120, San Pedro de la Paz, 4133515, Concepción, Chile.

2 PhD Program in Molecular Biotechnology, Faculty of Biological Sciences, University of

Concepción, Concepción, Chile.

3 PhD Program in Applied Clinical Sciences, Faculties of Dentistry and Pharmacy, University

of Concepción

†The authors contributed equally to the development of the manuscript.

Corresponding Author:

*Elard S. Koch

MELISA Institute, Dalcahue 1120, San Pedro de la Paz, 4133515, Concepción, Chile

Telephone +56 412467242 E-mail: ekoch@melisainstitute.org

Abstract

Proteomic studies of the female reproductive system have the potential to advance women's

reproductive health and improve understanding of fertility-related biological processes.

Cervicovaginal fluid (CVF), a complex mixture of uterine, cervical, and vaginal secretions,

represents a valuable source of molecular information reflecting time-dependent molecular

changes across the menstrual cycle. However, large-scale biomarker discovery in CVF remains

challenging due to limitations in sensitivity, reproducibility, and data completeness in mass

spectrometry–based workflows, particularly within repeated-measures longitudinal study

designs.

Here, we developed and evaluated a standardized high-throughput dia-PASEF–based

proteomics workflow for longitudinal repeated-measures analysis of CVF samples. These

samples were collected day-by-day across an ovulation-anchored 7-day window (day 0) and

the subsequent six post-ovulatory days within a prospective preconception cohort (EARLY-

PREG). This data-independent acquisition approach was directly compared with a

conventional DDA-FracOffline strategy.

Across a 7-day ovulation anchored window, DDA-FracOffline detected 2,817 quantifiable

proteins, whereas dia-PASEF identified 4,229 quantifiable proteins (approximately 50%

increase), with mean coefficients of variation $9.37 \pm 1.75\%$ and $5.27 \pm 0.68\%$, respectively.

Using day 0 (ovulation day) as the time reference for day-to-day comparisons, dia-PASEF

identified higher numbers of differentially expressed proteins (DEPs) than did DDA-

FracOffline across pairwise day comparisons (952–1,116 DEPs for dia-PASEF versus 161–

460 DEPs for DDA-FracOffline). Pathway enrichment analyses demonstrated broader

biological coverage using dia-PASEF. Furthermore, when evaluated against a literature-

reported panel of clinical biomarker candidates relevant to female reproductive tract

pathophysiology, the dia-PASEF workflow showed improved quantitative consistency and

enhanced dynamic range sensitivity.

These findings indicate that the implemented dia-PASEF approach provides a sensitive,

reproducible, and scalable workflow for longitudinal repeated-measures proteomics of CVF.

The method is adaptable to other biofluids and supports robust investigation of time-dependent

molecular signatures associated with key biological pathways under physiologically relevant

conditions in female reproductive system research.

Word count: 295

Keywords: Cervicovaginal fluid, High-throughput proteomics, dia-PASEF, Menstrual Cycle,

Biomarkers, Women's health.

Introduction

Proteomic studies of the female reproductive system are increasingly recognised as relevant

for advancing women's reproductive health and fertility research. At the molecular level,

insights gained from proteomic studies of tissues and biofluids[1] may contribute to our

understanding of the pathophysiology of different biological systems. Despite its importance,

the proteome and its time-dependent molecular changes in female reproductive fluids and

tissues under physiological and pathological conditions remain relatively underexplored [2–4].

Furthermore, despite the accelerated development of proteomics research, the discovery of

reliable biomarkers remains challenging, mainly due to methodological and analytical

limitations [5].

Cervicovaginal fluid (CVF) is recognised as a relevant biofluid source for biomarker discovery

in proteomics because of its continuity with the female reproductive tract and pivotal role in

fertility, pregnancy outcomes, and the local immune responses [6–11][12,13]. As a noninvasive source

of biological information, CVF reflects physiological and pathological changes, including the

menstrual cycle, pregnancy, and disease progression. Recent studies have linked specific

proteins in CVF to endometriosis [14,15], pregnancy-related complications [16,17] and several cancer

types, such as ovarian, endometrial, and cervical malignancies [6–11].

High-throughput proteomics has substantially advanced protein identification and

quantification. However, most studies rely on the data-dependent acquisition (DDA) of

proteins, a time-consuming workflow with limitations in quantitative capabilities,

reproducibility, and accuracy, particularly in large-scale longitudinal analyses with repeated

measures over time[18]. In the search for new strategies to obtain a more complete proteomic

analysis, data-independent acquisition data-independent acquisition (DIA)-based

methodologies have recently been developed[19]. For example, Njoku and collaborators [7]

recently applied a DIA method using sequential window acquisition of all theoretical fragment

ion mass spectra (SWATH-MS) to analyse CVF samples, which enabled the quantification of

a greater number of proteins compared with a standard DDA approach.

Addressing DDA limitations is important for improving clinical applications of CVF proteomics, particularly through longitudinal cohort studies [20,21] that enable the identification of biomarkers and the characterisation of time-dependent pathophysiological changes [22,23]. In fact, following biomarker variation over time may reveal molecular signatures linked to specific biological processes, offering additional insight into the course of female reproductive health and disease. Despite its potential, studies applying spectral library-based DIA to CVF are relatively rare compared with studies applying the traditional DDA, which has long been the dominant approach [24,25]. Furthermore, to date, no proteomic studies have systematically evaluated longitudinal changes in the CVF proteome across consecutive days of the menstrual cycle.

Although SWATH-MS has been explored as an alternative DIA approach to assess the CVF proteome, its reliance on fixed isolation windows may introduce spectral interferences that potentially limit resolution. With respect to new technologies that address this limitation, 4D proteomics, enabled by timsTOF mass spectrometry, integrates trapped ion mobility spectrometry (TIMS) with MS parallel accumulation-serial fragmentation (PASEF), increasing proteome resolution and coverage [26–28]. In this context, DIA strategies such as parallel accumulation–serial fragmentation combined with data-independent acquisition (dia-PASEF) have been applied as quantitative research tools [29] for complex biofluids such as plasma, where ionic mobility enables improved separation of ions based on their shape, size, and charge [26].

In this study, we aimed to implement and validate an optimised and reproducible dia-PASEF method for high-throughput time-dependent proteomic analyses of CVF samples collected from menstrual cycles of women participating in the EARLY-PREG longitudinal preconception open cohort [30]. The new dia-PASEF approach was compared with the traditional DDA coupled with the offline peptide fractionation (DDA-FracOffline) method. We hypothesised that the dia-PASEF approach would provide greater proteome coverage and reproducibility compared with traditional DDA, supporting its application for biomarker discovery in longitudinal studies of women's reproductive health, fertility, and early pregnancy.

Methods

1.   EARLY-PREG Cohort

EARLY-PREG (ClinicalTrials.gov identifier NCT07358026) is a preconception longitudinal open cohort designed to investigate maternal–embryonic communication at the ultra-early stages of conception through the serial and standardised collection of multiple biofluids, including CVF. Within this cohort, synchronised and well-documented samples were used to compare dia-PASEF with the traditional DDA approach coupled with offline peptide fractionation (DDA-FracOffline).

2.   CVF longitudinal samples

The CVF samples for this proteomics MS implementation and validation study were obtained from the biorepository of the EARLY-PREG preconception cohort. This biorepository includes different biofluids from 223 female volunteers collected daily during their menstrual cycles from the end of the menstrual period, which represents the beginning of a new cycle. Ovulation was determined by quantifying the luteinising hormone (LH) surge in urine. The samples were collected from the day after the end of menstruation until the 14th day post ovulation, as determined by the LH surge in each cycle, using a previously described method [31] which detects ovulation within ±1 day (95.7% confidence). LH concentrations were determined through radioimmunoassay (IRMA) (Barnafi-Krause Laboratory, Santiago, Chile). This approach allowed LH to be defined as a day 0 (*d0*), which served as a cycle-anchored time reference for synchronising repeated measures across individuals.

Participants were grouped into three cycle categories: conception, non-conception, and abstinence cycles. Due to the methodological focus of this validation study, homogeneity was prioritised over sample size. A subgroup of CVF samples from six women (n=6) belonging to non-conception cycles was selected according to criteria that controlled for factors such as body mass index, age, menstrual cycle length, and reproductive history.

To enable a within-individual repeated-measures longitudinal analysis, we defined an ovulation-anchored luteal phase window comprising seven consecutive days (*d0–d6*). Women were selected if at least seven consecutive post-ovulatory CVF samples were available in the

biorepository. To minimise intra- and inter-individual variability and reduce heteroscedasticity in repeated-measures analyses, we further prioritised homogeneity within selected individuals by considering menstrual cycle length, menstruation duration, age, sampling completeness across days, and other relevant variables within comparable ranges. Detailed characteristics of the selected participants are provided in Table 1.

3.   Protein extraction and processing for MS analysis

CVF aliquots (100–500 µL) were thawed on ice and combined with equal volumes of 100 mM NH4HCO3 and 100 mM DTT. The mixture was homogenised by vortexing, incubated at 95 °C for 15 minutes, and cooled on ice for 5 minutes. The samples were then subjected to cold ultrasound disruption at 4 °C (10-second on/off pulses at 50% amplitude) and subsequently centrifuged at 19,000 × g for 20 minutes at 4 °C. The supernatant (soluble phase) was carefully separated, while the pellet (insoluble phase) was retained for further processing.

The soluble phase was concentrated in Vivaspin tubes (10,000 MWCO filter, Sartorius), washed with 400 µL of ultrapure water, and centrifuged at 12,000 × g for 10 minutes at 4 °C. The filtrate (<10,000 Da) was dried in a SpeedVac and stored at -20 °C, while proteins retained on the filter (>10,000 Da) were recovered by washing with ~600 µL of water, combined, and dried. The insoluble pellet and soluble protein concentrate were resuspended in 8M urea with 25 mM NH_4HCO_3. The mixture was sonicated on ice, and centrifuged at 19,000 × g for 15 minutes at 4 °C. The protein content was quantified using a Qubit protein assay (Invitrogen, #Q33212).

For MS preparation, 300 µg of total protein from the soluble and insoluble phases was reduced with 20 mM DTT in 25 mM NH_4HCO_3 at 25 °C for 1 hour. Alkylation was performed with 20 mM iodoacetamide in 25 mM NH_4HCO_3 in the dark for 1 hour. The samples were diluted eightfold with 25 mM NH_4HCO_3 and digested with sequencing-grade trypsin (#V5071, Promega) at a 1:50 protease/protein ratio for 16 hours at 37 °C. Digestion was stopped by adding 10% formic acid. Peptides were cleaned using Sep-Pak C18 Spin columns (Waters), dried in a rotary concentrator at 40 °C, and stored for subsequent MS analysis.

4.   DDA-FracOffline

4.1. Peptide Fractionation

Offline high-pH reversed-phase fractionation of CVF peptides was performed using a protocol adapted from our previously published tear proteomics workflow [32]. A total of 200 µg of tryptic peptides from soluble and insoluble CVF phases were separated using an ÄKTA avant 25 system with refrigerated fraction collection at 6° C. Peptides were loaded onto a BHE reversed-phase column (2.1 cm × 5 cm, Waters) at pH 10 and a flow rate of 0.2 mL/min. The binary gradient increased linearly from 3% to 40% buffer B (90% ACN in 5 mM NH_4HCO_2) over 30 minutes, followed by increases to 60% over 15 minutes, and to 85% in the final 5 minutes. We collected a total of 24 fractions (400 µL each), which were vacuum-dried and then reconstituted in water containing 2% ACN and 0.1% FA. These fractions were concatenated into 8 final fractions.

4.2. Mass Spectrometry

nLC–MS was performed on a NanoElute (Bruker Daltonics) system coupled online with a hybrid TIMS-quadrupole TOF mass spectrometer, timsTOF Pro (Bruker Daltonics, Germany), via a nanoelectrospray ion source (CaptiveSpray, Bruker Daltonics) [33]. For long gradient nLC–MS/MS runs, we followed the standard protocol described by Meier et al., 2021. Approximately 200 ng of peptides were separated onto an Aurora series reversed-phase column (25 cm × 75 µm ID, 1.9 µm, IonOpticks, Australia) at a flow rate of 400 nL/min in an oven compartment heated to 50 °C. For the analysis of CVF off-line fractionated samples, we applied a multi-step gradient beginning with an increase from 2% to 17% B over 60 minutes, progressing to 25% B in 30 minutes, then to 37% B in 10 minutes, and finally to 95% B in 10 min, which was held for 10 min. The column was equilibrated using 4 volumes of solvent A. The mass spectrometer was operated in data-dependent PASEF [34] mode, consisting of 1 TIMS-MS survey and 10 PASEF MS/MS scans per acquisition cycle. Mobility values were acquired across a 1/K0 range of 1.6 to 0.6 Vs cm-2, using equal ion accumulation and ramp time of 100 ms each in the dual-TIMS analyser.

4.3. Data searching

Computational processing of DDA data was performed using the FragPipe v19.1 software. The pipeline integrates MSFragger (version 3.7)[35] search engine, for peptide-spectrum matching,

Philosopher (version 3.4.13)[36] for FDR control and validation, and EasyPQP (https://github.com/grosenberger/easypqp; version 0.1.9) for spectral library generation. Raw (.d) files were used as input for MSFragger searches. Protein identification was conducted against reference proteome of *Homo sapiens* (UP000005640) from UniProt/SwissProt (reviewed sequences only; downloaded on Feb. 15, 2021), supplemented with database of common contaminant proteins in MS experiments available in FragPipe. Decoy sequences were generated by reversed protein sequence entries to enable target-decoy estimation. For MSFragger analysis, mass tolerance for precursor and (initial) fragments were set to 20 ppm. The enzyme specificity was defined as 'strict trypsin', allowing fully tryptic cut and a maximum of two missed cleavages. Carbamidomethylation of cysteine was included as a fixed modification, whereas methionine oxidation and N-terminus acetylation were set as variable modifications. The final spectral library was filtered to 1% protein- and peptide FDR levels.

5.   dia-PASEF

5.1   Mass spectrometry

The timsTOF Pro was operated in dia-PASEF mode with the following settings: mass range, 100 to 1700 m/z; ion mobility range, 1/k0 start, 0.57 V/cm2, end, 1.47 V/cm2; ramp and accumulation times, 100 ms; capillary voltage, 1600 V; dry gas, 3 L/min; and dry temperature, 160 °C. The dia-PASEF Ion Mobility Parameters were as follows: Each cycle consisted of a one MS1 full scan and 64x MS2 windows covering 400–1200 m/z and 0.57–1.46 1/K0. Each window was 25 Th wide by 0.2 V s/cm2 high. There was an overlap of 0.05 in 1/K0 and no overlap in m/z. The cycle time was 1.80 seconds. The CID collision energy was 20 to 52 eV as a function of the inverse mobility of the precursor [24].

5.2   Data search

For the construction of the DDA spectral library, a pooled of all samples of tryptic-digested peptides was used. For peptide fractionation, mass spectrometry and data searching, the method described in the DDA section was used (see methods sections 3.1, 3.2 and 3.3). Proteomic data analyses were performed on a high-performance computing server with dual AMD EPYC 7552 48-core processors (2.20 GHz) and 512 GB of RAM. Raw dia-PASEF data were processed via DIA-NN v1.7.15 software [37], using the spectral library generated in the previous step. Mass

accuracy thresholds were set to a default average of 10 ppm for MS1 and MS2 spectra. Match-between-runs (MBR) was enabled; quantification mode was set to "any LC (high accuracy)". All remaining settings were left default. Identifications were filtered using a precursor-level q value < 1% and a global protein-level q value < 1%.

6.   Bioinformatics and statistical analysis

The intensity matrix reports from MSFragger and DIANN were exported and processed in the R statistical environment. The intensity values for each run were normalised by adjusting the medians. Missing values were imputed via the missForest algorithm [38], applying the criterion that the intensity value should be present in at least 50% of the samples per analysed category [39]. Longitudinal differentially expressed proteins (DEPs) along the menstrual cycles were represented both as absolute and relative numbers (%), and the significant difference was determined by using a using Bayesian t-tests for pairwise day comparisons (e.g., d0 vs. dn, d1 vs. dn), considering the normalised intensity means of biological replicates [40]. AProteins were considered statistically significant at p < 0.05. Exploratory analysis and data visualisation were performed in R (v.3.6.0) using EnhancedVolcano (v.1.2.0), ComplexHeatmap (v.2.0.0), and standard base packages. The coefficients of variation were determined using the statistically significant differential expression values of each methodology for both dia-PASEF and DDA-FracOffline. Quantifiable proteins were defined as those that were consistently detected across each condition and presented measurable relative abundance values.

7.   Pathway and tissue enrichment analysis

Pathway enrichment analysis was developed using ReactomePA (v.1.42.0), which queries the human database with log2 fold change (logFC) and p value data obtained for each statistical comparison. For the analysis of enrichment by human systems, tissues and cells, we used the TISSUES 2.0 database [41], considering the same statistical parameters used for the pathway analysis through topGO (v.2.5.0). Boxplots were generated to represent the distribution of protein intensities using ggpubr (v.0.6.0). Statistical comparisons between groups were conducted using t tests and chi-square tests with rstatix (v.0.7.2). Adjusted p values were calculated without additional correction, and significance levels were directly annotated on the graphs. The z score was calculated based on the logFC of each protein belonging to the designated reactome and tissue categories using the GOplot (v.1.0.2) package. Importantly,

this z score is not equivalent to the conventional z score; instead, it provides a directional estimate indicating whether a biological process, molecular function, or cellular component tends to be upregulated (positive value) or downregulated (negative value). The z score was determined based on the number of proteins assigned as upregulated (logFC > 0) and those classified as downregulated (log FC < 0), labelled as "up" and "down" in the dataset.

8.   Biomarker selection

To assess the efficiency of dia-PASEF in biomarker detection, an FDA-proposed biomarker panel derived from a previously published study [42], was used to directly compare the ability of dia-PASEF and DDA-FracOffline to detect and quantify these clinically relevant proteins. In addition, we conducted an extensive literature-based curation of candidate proteins associated with physiological and pathological conditions of the female reproductive tract. Searches were performed using keywords including "menstrual cycle", "ovarian carcinoma", "endometrial carcinoma", "cervical carcinoma", and "endometriosis", integrating evidence from proteomic, transcriptomic, and genomic studies.

9.   Data availability

Proteomics data can be accessed through the ProteomeXchange Consortium via PRIDE, with the dataset identifier PXD071350 and PXD071584.

10.   Ethics approval and consent to participate

The EARLY-PREG protocol was approved by the Ethics Committee of the Servicio de Salud de Concepción, Chile (CEC: 17-03-06). All participants provided written informed consent prior to enrolment. All procedures were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.

RESULTS

1.   Patient Characterization and Sampling

After screening all non-conception fertile cycles of women with complete records in the EARLY-PREG cohort database, we selected six women with homogeneity in terms of age, weight, height, BMI, waist circumference, age at menarche, menstrual cycle length, and menstruation length. The length of the menstrual phase of the cycle (5.8 ± 0.4), the length of the fertile cycle (29.0 ± 3.0), age (32.3 ± 3.6), and other variables were within comparable ranges. Detailed participant characteristics are provided in Table 1. Forty-two CVF samples (n=42) stored at -80 °C were processed for protein extraction and tryptic digestion and then analysed with the two mass spectrometry methodologies (Figure 1A) as described in the Methods. To minimise batch effects, all 42 samples were analysed on the timsTOF Pro mass spectrometer within the same calibration batch. This included 336 chromatographic runs using the DDA approach and 42 direct runs using dia-PASEF over a two-week period. Thus, with each protocol, we obtained a 7-day time series (*d0* to *d6*) of CVF proteomes for each woman. For each analytical workflow, this design yielded a within-individual repeated-measures time series comprising a 7-day ovulation-anchored window (d0–d6) of CVF proteomes per participant.

341 **Table 1**: Information on the patients whose samples were used in the proteomic experiments.

Factors	Women (n=6)					
	P1	**P2**	**P3**	**P4**	**P5**	**P6**
Age (mean ± SD)	32.3 ± 3.6					
Weight (kg)	62	57	66	67	60	74
Height (m)	1.52	1.60	1.68	1.61	1.58	1.7
BMI[1]	26.8	22.2	24.4	25.8	24	25.6
Waist circumference (cm)	72	64	66	70	68	82
Age at menarche (mean ± SD)	12.7 ± 1.2					
Menstrual cycle length[2] (days)	28	30	24	30	29	33
Menstruation length[3] (days)	5	6	6	6	6	6

342 [1]Body mass index (BMI) was calculated as weight (kg) divided by height squared (m²).
343 [2]Menstrual cycle length refers to the number of days from the first day of menstruation to the first day of the next
344 cycle.
345 [3]Menstruation duration corresponds to the number of days of menstrual bleeding per cycle.

Figure 1. Proteomics workflow for the longitudinal repeated-measures analysis of CVF. Schematic representation of the experimental design and strategies used to analyse CVF samples from women in the EARLY-PREG cohort. (A) CVF samples were collected across a 7-day ovulation-anchored window (d0–d6) of the menstrual cycle, enabling within-individual repeated-measures analysis. (B) Two nLC-MS/MS proteomics approaches were compared: DDA-FracOffline and dia-PASEF. Both workflows included protein extraction, digestion, and mass spectrometry analysis using the nanoElute system coupled to a timsTOF Pro instrument. The right panel summarises the comparative evaluation of both methods, including missing values, number of quantified proteins, coefficient of variation, abundance rank distribution, and their ability to identify putative biomarkers and capture time-dependent longitudinal proteomic changes.

2. Quality Control Factors analysed to compare DDA-FracOffline and the dia-PASEF

We conducted a comparative analysis focusing on key quality control parameters, including reproducibility, the proportion of missing values, and protein identification and quantification performance. First, reproducibility was assessed using correlation coefficients between biological replicates. The mean correlation coefficient was approximately 0.70 for DDA-FracOffline and 0.90 for dia-PASEF (Figure S1). Second, we evaluated the proportion of missing values across samples. The dia-PASEF workflow showed a substantially lower proportion of missing values compared with DDA-FracOffline, which reached up to 75% at its lowest detection point (Figure 2B). Third, correlation analysis across samples demonstrated lower inter-sample consistency for DDA-FracOffline relative to dia-PASEF (Figure 2A). Next, we analysed protein identification and quantification performance. DDA-FracOffline identified a total of 9,593 proteins, whereas dia-PASEF identified 5,986 proteins. However, when considering quantifiable proteins (identified and consistently measured across samples), DDA-FracOffline quantified 2,817 proteins, whereas dia-PASEF quantified 4,229 proteins (Figure 2E, left), corresponding to a 50% higher quantification yield for dia-PASEF. The mean coefficient of variation (CV) for quantifiable proteins—calculated as the average of individual protein CVs across all samples—was $5.27 \pm 0.68\%$ for dia-PASEF and $9.37 \pm 1.75\%$ for DDA-FracOffline (Figure 2E, centre) indicating improved quantitative consistency in the dia-PASEF workflow. Finally, across the ovulation-anchored time series (d0–d6), DDA-FracOffline identified between 1,491 and 7,183 proteins across time points (Figure 2C), whereas dia-PASEF detected between 3,811 and 5,398 proteins across time points (Figure 2D). Although DDA-FracOffline showed broader overall protein identification, dia-PASEF demonstrated greater consistency in protein detection across the ovulation-anchored repeated-measures time series.

Figure 2. Quality control of proteomic data obtained by DDA-FracOffline and dia-PASEF. (A) Pearson correlations between chromatographic runs, positive correlations (red) and no correlations (white). (B) Bar plots of the proportion of missing values (%MVs) for each sample, showing present values (blue) and missing values (red). (C-D) Number of identified proteins per sample: green bars correspond to DDA-FracOffline (C), and orange bars correspond to dia-PASEF (D). (E) Overview of identified and quantifiable proteins: bar plots showing the total numbers of identified proteins (left) and quantifiable proteins (centre) for DDA-FracOffline (green) and dia-PASEF (orange). The violin plot (right) represents the coefficient of variation (%CV) for each method. The Venn diagram illustrates the shared and unique proteins identified by each analytical strategy. (F) Number of differentially expressed

proteins (DEPs) identified by each strategy through longitudinal comparisons at day d0. The bar plot displays the total number of DEPs obtained by each strategy, indicating the statistical significance (***, p value < 0.001) above the bars. The statistical significance was determined using chi-square tests for categorical variables. DEPs were identified using DDA-FracOffline (green) and dia-PASEF (orange).

2.1. Differential Protein Expression

Following quality control, we assessed the time-dependent dynamics of differentially expressed proteins (DEPs) across the menstrual cycle to characterise variations in protein abundance in CVF within the ovulation-anchored, repeated-measures 7-day window (*d0–d6*). Comparative analyses revealed significant differences between methodologies in the detection and quantification of DEPs across longitudinal CVF samples (Figure S2). At most time points, dia-PASEF identified higher absolute and relative numbers of DEPs than did DDA-FracOffline, e.g. 985 (23%) vs. 251 (8.9%) between *d0* and *d1* and 1,057 (24.9%) vs 161 (5.7%) between *d0* and *d2*. From d0 to d6, dia-PASEF maintained a more stable detection rate (Figure 2F). These findings indicate that dia-PASEF enables more consistent detection and quantification of differentially expressed proteins in longitudinal repeated-measures designs, facilitating the capture of time-dependent proteomic changes across the cycle (Figure 2F and Figure S2).

3. Longitudinal enrichment analysis of pathways, systems, tissues and cells

To interpret the functional relevance of the quantified proteins, we performed tissue and pathway enrichment analyses. We evaluated tissue representation based on DEPs identified across longitudinal CVF comparisons within the ovulation-anchored repeated-measures window (Figure S3). The analysis revealed enrichment in tissues associated with the female reproductive system, including the uterus and uterine cervix, as well as immune-related tissues. The dia-PASEF workflow demonstrated broader and more consistent tissue coverage, particularly at later time points (*d5* and *d6*), with elevated enrichment scores (-log10 adjusted p value) and the highest protein densities. We further examined the biological processes associated with the differential protein profiles detected across the 7-day window. Common pathways identified with both strategies between time points *d0* to *d6* (Figure 3) included 'Formation of the cornified envelope', 'Metabolism of proteins', and 'Processing of capped

intron-containing pre-mRNA'. Additional pathways, such as 'Signalling by RHO GTPases' and 'Mitotic Metaphase/Anaphase Transition' were consistent with cell signalling and cell-cycle–related processes (Figure 3). Compared with DDA-FracOffline, dia-PASEF showed increased pathway coverage and enrichment across the time-dependent series.

Figure 3. Differentially expressed proteins and biological pathways identified via longitudinal analysis using DDA-FracOffline and dia-PASEF. Reactome enrichment analysis, emphasising the most abundant biological pathways. DEPs were derived from longitudinal comparisons within each method. The Y-axis includes Reactome pathways and X-axis represents the activation coefficient (Z score) of each pathway.

4. Identification of Physiological and pathological biomarkers

We evaluated the ability of each strategy to identify and quantify known biomarkers of physiological and pathological processes. We began with a set of disease biomarkers proposed by the U.S. Food and Drug Administration (FDA-proposed biomarkers) [42], focusing on fluids related to various pathologies and examining literature-curated sets of proteins related to female reproductive-tract pathophysiology (Table S1).

4.1 Comparison of FDA-proposed biomarkers via DDA-FracOffline and dia-PASEF

The FDA-proposed biomarker panel comprised 121 proteins detectable in biological fluids and associated with female reproductive pathologies [42]. Figure 4 compares the ability of each strategy to detect these biomarkers in CVF. Dia-PASEF and DDA-FracOffline identified 91 and 76 of the 121 proteins, corresponding to 75% and 63%, respectively; 92 proteins (76%) were identified by both strategies (Figure 4A). A protein rank-abundance plot demonstrated that dia-PASEF captured proteins across a broader dynamic range compared with DDA-FracOffline (Figure 4B). Fifteen FDA biomarkers were unique to dia-PASEF (NT5E, ACE, GLA, C4A, C1QC, ACP5, PROS1, BRAF, VWF, GALT, MSH2, TFRC, TOP2A, and BTD), whereas the protein GFAP was detected only by DDA-FracOffline (Figure 4B). Overall, dia-PASEF showed improved quantification consistency and reproducibility relative to DDA-FracOffline for the detection of clinically relevant biomarker candidates in CVF. 4.2 Selected biomarkers from literature review

A literature-based curated list of biomarkers previously reported in pregnancy, cervical, ovarian, and endometrial carcinomas, as well as endometriosis, is provided in Table 2. We examined the time-dependent behaviour of four representative biomarkers selected from the curated list to illustrate the longitudinal detection capability of the dia-PASEF workflow (Figure 4C–G). To illustrate the longitudinal repeated-measures capability of dia-PASEF in detecting clinically relevant proteins, we tracked insulin-like growth factor-binding protein 4 (IGFBP-4), implicated in early pregnancy and foetal growth restriction; MUC1, a mucin contributing to reproductive tract integrity; and the ovarian cancer biomarkers CA-125 (MUC16) and HE4 (WFDC2). Insulin-like growth factor-binding protein 4 (IGFBP4) has been associated with early pregnancy and foetal growth restriction (Figure 4C, Figure S4). MUC1, expressed throughout the female reproductive tract—including endocervical, ectocervical, and vaginal epithelia—plays a role in maintaining epithelial barrier function (Figure 4D, Figure S4). Both proteins are physiologically expressed across the menstrual cycle. In addition, clinically relevant biomarkers CA-125 (Figure 4E, Figure S4) and HE4 (Figure 4F, Figure S4), encoded by MUC16 and WFDC2 respectively, were consistently detected. Longitudinal analysis across the ovulation-anchored repeated-measures window (*d0–d6*) revealed significant day-to-day variation in all four proteins (Figure 4C–G; Figure S4), supporting the suitability of dia-PASEF for time-dependent biomarker profiling.

Figure 4. Biomarker identification and longitudinal protein analysis from *d0* to *d6* by DDA-FracOffline and dia-PASEF. (A) Venn diagram illustrating the overlap of proteins identified and FDA-approved biomarkers, highlighting 76 shared proteins and unique identifications for each strategy. (B) Abundance rank plot of proteins identified in CVF samples via DDA-FracOffline alone (green), dia-PASEF alone (orange), and both strategies (purple). FDA approved biomarker proteins are highlighted. The right panel displays the density distribution of protein abundances. (C, D) Box plots show longitudinal expression patterns of the pregnancy-pathology-associated gene IGFBP4 and the physiological protein MUC-1. (E, F) Box plots of MUC16 and WFDC2. (***, p value < 0.001; **, p value < 0.01; *, p value < 0.05) (G) Trajectory of the longitudinal expression of IGFBP4, MUC1, MUC16 and WFDC2.

Table 2: Summary of biomarkers associated with female pathologies.

Pathology	Gene Symbol	References
Pregnancy pathologies	*FBLN1*	43,44
	NCSTN	45,46
	ACTR2	45,46
	NDUFB3	47
	IGFBP4	48–50
Cervical carcinoma	*MUC5B*	51–53
	ANXA2	51–54
	ACTN4	51–54
	PKM	53,54
Ovarian carcinoma	*MUC16*	55–59
	NT5E	60
	WFDC2	9,58–60
	KLK5	61
	MUC1	62,63
	CHI3L1	56,57
Endometrial carcinoma	*MUC16*	64–66
	CTTNB1	6,64,67,68
	WFDC2	64,65,68
	MMP9	64,68,69
Endometriosis	*TOP2A*	70,71
	S100A8	15,72–74
	LCN2	15
	LUM	72,74–76

Discussion

CVF is well established as a valuable biological source for research on the pathophysiology of the female reproductive tract. This biofluid contributes to multiple biological processes, including barrier function, immune responses, microbiota preservation, sperm transport, and menstrual cycle regulation. The emergence of advanced proteomics workflows and MS instrumentation provides opportunities for large-scale identification of reproductive health biomarkers in CVF [5]. The present study evaluated the performance of dia-PASEF as a high-throughput proteomic workflow for analysing CVF in longitudinal repeated-measures designs with time-series sampling. To our knowledge, this is among the first applications of dia-PASEF to CVF collected across consecutive days of the menstrual cycle, showing improved performance relative to DDA-FracOffline. We observed greater quantification depth, reproducibility, and sensitivity for low-abundance proteins following comprehensive comparative analyses. The reduced variability (CV = 5.27 ± 0.68%) and lower proportion of missing values enabled more consistent quantification across samples, improving the robustness of longitudinal analyses compared with DDA-FracOffline (Figure 2). These findings indicate that dia-PASEF supports reliable tracking of protein abundance over time, facilitating the investigation of time-dependent molecular changes in CVF.

Studies of longitudinal effects are essential for assessing the development of physiological phenomena over time, such as ultra-early pregnancy, during which the earliest stages remain poorly understood. These analyses are also relevant for monitoring disease progression and therapeutic responses from a pathophysiological perspective. However, longitudinal analysis of CVF remains technically challenging due to the intrinsic complexity of this biofluid and the limited availability of well-characterised repeated-measures datasets spanning the menstrual cycle. In this context, the application of advanced acquisition strategies such as dia-PASEF represents a methodological advancement, as it provides analytical features suited for complex biofluids and improved detection of low-abundance proteins in time-dependent study designs.

We observed a shorter data processing time for dia-PASEF (a few minutes per sample) than for DDA-FracOffline (approximately 1–2 hours per sample), supporting its suitability for high-throughput longitudinal repeated-measures proteomic studies. The higher reproducibility observed with dia-PASEF is consistent with its systematic precursor selection strategy, which enhances proteome depth and sensitivity [77]. In contrast, the sequential precursor selection

inherent to DDA-FracOffline is associated with greater variability and reduced efficiency in
protein sampling, limiting its applicability in large-scale and time-dependent study designs.

The ability of dia-PASEF to capture comprehensive fragmentation data within a single
acquisition cycle contributes to improved protein identification, reduced missing values, and
broader proteome coverage. The greater quantitative stability observed with dia-PASEF further
supports its application in large-scale longitudinal proteomics, in line with previous reports
describing the analytical advantages of data-independent acquisition strategies [26].

Although both methodologies allow in-depth protein identification, we observed that dia-
PASEF enabled more consistent protein quantification than DDA-FracOffline, primarily
because the latter showed lower quantifiable protein coverage and a higher proportion of
missing peptides [29]. When comparing dia-PASEF with other DIA approaches applied to CVF,
such as SWATH-MS–based methods [7], dia-PASEF identified and quantified a substantially
higher number of proteins. Previous proteomic studies using SWATH-MS in CVF have
reported limitations including reduced sensitivity for low-abundance proteins, peptide co-
fragmentation effects [26], and higher proportions of missing values.

Enrichment analyses enabled exploration of the functional relevance of identified proteins
contributing to CVF pathophysiology (Figure 3). Both strategies highlighted pathways related
to cellular signalling, protein metabolism, immune responses, interleukin signalling, mitotic
metaphase–anaphase transition, mRNA splicing, and RHO GTPase signalling, which are
implicated in reproductive system biology [78,79]. dia-PASEF showed higher enrichment scores
across the time-dependent window, suggesting improved biological coverage. For example,
neutrophil gelatinase-associated lipocalin (NGAL; encoded by LCN2), involved in neutrophil
degranulation [15] signalling pathways, was consistently detected (Figure 3, Figure 4H).

Tissue enrichment analysis confirmed the biological relevance of the identified proteins,
highlighting associations with tissues of the female reproductive system [80], including the uterus
and uterine cervix. These findings are consistent with the ability of dia-PASEF to provide
system-specific sensitivity and time-dependent biological profiling, particularly for
reproductive and immune-related functions in longitudinal CVF proteomics.

We compared proteins identified by dia-PASEF and DDA-FracOffline with the FDA-proposed biomarker panel [42] . Using the dia-PASEF workflow, we identified 15 unique quantifiable FDA-proposed biomarkers, compared with one unique quantifiable biomarker detected using DDA-FracOffline (Figure 4A). Dia-PASEF identified biomarkers across a broader dynamic range, including both high- and low-abundance proteins (Figure 4B), supporting its suitability for comprehensive biomarker profiling in CVF. These findings indicate improved detection performance of dia-PASEF for FDA-proposed biomarkers within this longitudinal repeated-measures design.

Proteins detected at low abundance were linked to biological processes relevant to menstrual cycle regulation and gynaecological diseases. For example, C1QC and VWF are involved in immune responses and vascular regulation. A broader and more uniform dynamic range was observed with dia-PASEF, likely reflecting improved signal-to-noise performance, a feature that is advantageous for longitudinal analyses in complex biofluids[34] such as CVF. As an additional strategy for evaluating clinically relevant biomarkers, dia-PASEF facilitated the detection of low-abundance proteins across the time-dependent repeated-measures window. IGFBP-4 (Figure 4C), whose levels have been associated with early pregnancy and foetal growth restriction [48,50] and MUC1 (Figure 4D), a mucin expressed throughout the female reproductive tract—including endocervical, ectocervical, and vaginal epithelia—were consistently detected. MUC1 plays a role in maintaining epithelial integrity and barrier function [62,63] .

We also detected CVF proteins associated with pathological processes, including alpha-actinin-4 (ACTN4) and annexin A2 (ANXA2), which have been reported in previous studies [51–53] (Table 2). In the context of gynaecological carcinomas, two clinically relevant proteins were identified: cancer antigen 125 (CA-125), encoded by the MUC16 gene (Figure 4E), and human epididymis protein 4 (HE4), encoded by the WFDC2 gene (Figure 4F). These proteins were detected in CVF samples collected across the ovulation-anchored window (*d0–d6*). Both biomarkers have been widely investigated in ovarian [58,59] and endometrial [64,65] carcinoma. Longitudinal analysis revealed significant day-to-day variation across the repeated-measures window (Figure S4). These findings suggest that dia-PASEF facilitates time-dependent monitoring of clinically relevant proteins in CVF, supporting its potential application in studies of pathologies related to the female reproductive tract.

Proteins present in CVF may also represent promising candidates for identifying longitudinal
pathophysiological markers. Owing to its reduced proportion of missing values and more
consistent time-dependent protein profiling, dia-PASEF generated a more complete
quantitative dataset (Figure 2B). This characteristic supports its application for tracking protein
dynamics over time in physiological processes, such as endometrial receptivity, as well as in
pathological contexts. A consistent pattern of protein variation was observed across specific
days of the cycle (Figure 4G, Figure S4), providing insight into defined physiological windows
within the ovulation-anchored repeated-measures framework. These findings support the
feasibility of longitudinal biomarker monitoring in CVF, including potential applications in
therapeutic follow-up studies.

This study is focused primarily on achieving methodological robustness to enable a reliable
comparison between strategies and to highlight the advantages of the dia-PASEF approach.
Despite the limited sample size, our parsimonious approach[81] minimises variability by
selecting a homogeneous subgroup of volunteers based on exclusion criteria that control for
factors such as body mass index, age, menstrual cycle length, and reproductive history.

The participants were also synchronised according to the surge in luteinising hormone from *d0*
to *d6* (peri-ovulatory to early luteal phase of menstruation), which minimised interindividual
variability. This approach enabled the selection of volunteers with complete repeated-measures
data for implementation and validation of the proteomic workflows, thereby minimising
technical and biological noise in biomarker identification. By using a within-individual
longitudinal framework with a semi-counterfactual structure, this design further reduced the
influence of population heterogeneity. Owing to the methodological scope and limited sample
size of the study, the findings are not directly generalisable to pathological conditions.
However, future expansion of the cohort to include participants with defined pathologies will
be necessary to evaluate the potential of dia-PASEF in identifying disease-specific biomarkers.
In addition, functional validation of candidate biomarkers will be essential to clarify how these
proteins are involved in specific physiological or pathological processes and to assess their
potential clinical relevance

This study demonstrates the suitability of dia-PASEF as a robust analytical platform for
longitudinal repeated-measures CVF proteomics, addressing limitations inherent to DDA-
based workflows and supporting biomarker discovery in fertility, early pregnancy, and

gynaecological research. Overall, this approach provides a scalable methodological framework for time-dependent proteomic investigations in complex reproductive biofluids.

Author's roles

E.S.K. led the study. M.H. and E.S.K. drafted the manuscript and conceptualised the study. E.S.K., M.H., and C.V. contributed to the study design. M.H. designed, supervised, and performed the proteomics methodology. P.S., B.A., and V.L. contributed to study conception. M.H., P.S., and G.N. developed the experimental system, performed the experiments, and analysed the data. F.C. and G.N. supported the experimental work. M.H., P.S., B.A., and V.L. reviewed and commented on manuscript drafts. E.S.K. revised the manuscript and approved the final version. E.S.K. is the guarantor of the study and accepts full responsibility for the integrity of the work.

Acknowledgements

The authors thank Dr. Ute Woehlbier (Center for Integrative Biology, Universidad Mayor) for English language editing. We also acknowledge Estefanía Nova-Lamperti (Molecular and Translational Immunology Laboratory, Department of Clinical Biochemistry and Immunology, Faculty of Pharmacy, Universidad de Concepción, Chile) for assistance with figure design. I.F.-M. received professional service fees from Fundación de Investigación San Ramón (FISAR), Concepción, Chile.

Funding

This work forms part of the EARLY-PREG preconception open cohort and has been supported by research grants awarded by Fundación de Investigación San Ramón (FISAR), based in Chile. The pilot study and first recruitment wave were supported by grants #MEL109112011 and #MEL109112011R4 awarded to E.S.K., C.V., and J.F.S. The second recruitment wave was supported by grants #MEL109112011R5 and #MEL131032017R1 awarded to E.S.K. The third wave was supported by grant #MEL205062018 awarded to E.S.K. and M.H. Current funding for the fourth recruitment wave and mass spectrometry research on maternal CVF is supported by grant REH042024-01 awarded to M.H., G.N., and E.S.K.

Conflict of interest

E.S.K. serves in an unpaid honorary capacity as a research advisor and reviewer for Fundación de Investigación San Ramón (FISAR). No other competing interests are declared.

References

1. Beutgen, V. M. & Graumann, J. Advances in aqueous humor proteomics for biomarker discovery and disease mechanisms exploration: a spotlight on primary open angle glaucoma. *Front. Mol. Neurosci.* **17**, 1397461 (2024).

2. Masina, R. & Caldas, C. Precision Cancer Medicine 2.0-Oncology in the postgenomic era. *Mol. Oncol.* **18**, 2065–2069 (2024).

3. Rafelski, S. M. & Theriot, J. A. Establishing a conceptual framework for holistic cell states and state transitions. *Cell* **187**, 2633–2651 (2024).

4. Holmes, C., Carlson, S. M., McDonald, F., Jones, M. & Graham, J. Exploring the post-genomic world: differing explanatory and manipulatory functions of post-genomic sciences. *New Genet. Soc.* **35**, 49–68 (2016).

5. Kaur Jawanda, I., Soni, T., Kumari, S. & Prabha, V. Deciphering the potential of proteomic-based biomarkers in women's reproductive diseases: empowering precision medicine in gynecology. *Biomarkers* **29**, 7–17 (2024).

6. Martinez-Garcia, E. *et al.* Cervical fluids are a source of protein biomarkers for early, non-invasive endometrial cancer diagnosis. *Cancers (Basel)* **15**, 911 (2023).

7. Njoku, K. *et al.* Comprehensive library generation for identification and quantification of endometrial cancer protein biomarkers in cervico-vaginal fluid. *Cancers (Basel)* **13**, 3804 (2021).

8. Njoku, K. *et al.* Detection of endometrial cancer in cervico-vaginal fluid and blood plasma: leveraging proteomics and machine learning for biomarker discovery. *EBioMedicine* **102**, 105064 (2024).

9. Hedlund Lindberg, J. *et al.* Toward ovarian cancer screening with protein biomarkers using dried, self-sampled cervico-vaginal fluid. *iScience* **27**, 109001 (2024).

10. Köse, B. *et al.* Identifying biomarkers for cervical neoplasia: A label-free proteomic analysis of cervicovaginal fluid. *Eur. Arch. Med. Res.* **40**, 36–43 (2024).

11. Gutiérrez, A. L. *et al.* Identification of candidate protein biomarkers for CIN2+ lesions from self-sampled, dried cervico-vaginal fluid using LC-MS/MS. *Cancers (Basel)* **13**, 2592 (2021).

12. Lacroix, G., Gouyer, V., Gottrand, F. & Desseyn, J.-L. The cervicovaginal mucus barrier. *Int. J.*
Mol. Sci. **21**, 8266 (2020).

13. Zegels, G., Van Raemdonck, G. A., Tjalma, W. A. & Van Ostade, X. W. Use of cervicovaginal
fluid for the identification of biomarkers for pathologies of the female genital tract. *Proteome*
Sci. **8**, 63 (2010).

14. Fernandez-Hermida, Y., Grande, G., Menarguez, M., Astorri, A. L. & Azagra, R. Proteomic
markers in cervical mucus. *Protein Pept. Lett.* **25**, 463–471 (2018).

15. Grande, G. *et al.* Cervical mucus proteome in endometriosis. *Clin. Proteomics* **14**, 7 (2017).

16. Zhao, Z. *et al.* Noninvasive cervicovaginal proteomic biomarkers for spontaneous preterm birth.
(2024).

17. Ueda, Y. *et al.* Hyposecretion of cervical MUC5B is related to preterm birth in pregnant women
after cervical excisional surgery. *Am. J. Reprod. Immunol.* **91**, e13832 (2024).

18. Birhanu, A. G. Mass spectrometry-based proteomics as an emerging tool in clinical laboratories.
Clin. Proteomics **20**, 32 (2023).

19. Fang, H. & Greening, D. W. An optimized data-independent acquisition strategy for
comprehensive analysis of human plasma proteome. *Methods Mol. Biol.* **2628**, 93–107 (2023).

20. Stefanakis, K., Samiotaki, M. & Mantzoros, C. S. 7562 longitudinal untargeted proteomics of
Leptin administration in lean humans under short- and long-term energy deficiency: Novel
physiological insights and pleiotropic immunomodulatory effects from two randomized, placebo-
controlled clinical trials. *J. Endocr. Soc.* **8**, (2024).

21. Viode, A. *et al.* Longitudinal plasma proteomic analysis of 1117 hospitalized patients with
COVID-19 identifies features associated with severity and outcomes. *Sci. Adv.* **10**, eadl5762
(2024).

22. Alesi, S. *et al.* Exploring causal associations between serum inflammatory markers and female
reproductive disorders: A Mendelian randomisation study. *Biomolecules* **14**, 1544 (2024).

23. Bruinvels, G., Hackney, A. C. & Pedlar, C. R. Menstrual cycle: The importance of both the
phases and the transitions between phases on training and performance. *Sports Med.* **52**, 1457–
1460 (2022).

24. Rice, S. J. & Belani, C. P. Optimizing data-independent acquisition (DIA) spectral library

workflows for plasma proteomics studies. *Proteomics* **22**, e2200125 (2022).

25. Staes, A. *et al.* Benefit of in silico predicted spectral libraries in data-independent acquisition

data analysis workflows. *J. Proteome Res.* **23**, 2078–2089 (2024).

26. Meier, F. *et al.* diaPASEF: parallel accumulation-serial fragmentation combined with data-

independent acquisition. *Nat. Methods* **17**, 1229–1236 (2020).

27. Skowronek, P. & Meier, F. High-throughput mass spectrometry-based proteomics with dia-

PASEF. *Methods Mol. Biol.* **2456**, 15–27 (2022).

28. Mun, D.-G. *et al.* Four-dimensional proteomics analysis of human cerebrospinal fluid with

trapped ion mobility spectrometry using PASEF. *Proteomics* **23**, e2200507 (2023).

29. Bader, J. M., Albrecht, V. & Mann, M. MS-Based Proteomics of Body Fluids: The End of the

Beginning. *Molecular & Cellular Proteomics : MCP* **22**, 100577 (2023).

30. Koch, E. S. *et al.* EARLY–PREG: A preconception longitudinal cohort of women seeking

pregnancy to investigate maternal-embryonic molecular signalling during the peri–implantation

window. *medRxiv* 2025.05.12.25326372 (2026) doi:10.1101/2025.05.12.25326372.

31. Godbert, S., Miro, F., Shreeves, C., Gnoth, C. & Johnson, S. Comparison between the different

methods developed for determining the onset of the LH surge in urine during the human

menstrual cycle. *Arch. Gynecol. Obstet.* **292**, 1153–1161 (2015).

32. Vera-Montecinos, A. *et al.* High throughput tear proteomics with data independent acquisition

enables biomarker discovery in allergic conditions. *Sci. Rep.* **15**, 31181 (2025).

33. Meier, F. *et al.* Online parallel accumulation-serial fragmentation (PASEF) with a novel trapped

ion mobility mass spectrometer. *Mol. Cell. Proteomics* **17**, 2534–2545 (2018).

34. Meier, F. *et al.* Parallel accumulation-serial fragmentation (PASEF): Multiplying sequencing

speed and sensitivity by synchronized scans in a trapped ion mobility device. *J. Proteome Res.*

14, 5378–5387 (2015).

35. Kong, A. T., Leprevost, F. V., Avtonomov, D. M., Mellacheruvu, D. & Nesvizhskii, A. I.

MSFragger: ultrafast and comprehensive peptide identification in mass spectrometry–based

proteomics. *Nature Methods* **14**, 513–520 (2017).

36. da Veiga Leprevost, F. *et al.* Philosopher: a versatile toolkit for shotgun proteomics data

analysis. *Nature Methods* **17**, 869–870 (2020).

37. Demichev, V., Messner, C. B., Vernardis, S. I., Lilley, K. S. & Ralser, M. DIA-NN: neural

networks and interference correction enable deep proteome coverage in high throughput. *Nature*

Methods **17**, 41–44 (2019).

38. Stekhoven, D. J. & Bühlmann, P. MissForest--non-parametric missing value imputation for

mixed-type data. *Bioinformatics* **28**, 112–118 (2012).

39. Lazar, C., Gatto, L., Ferro, M., Bruley, C. & Burger, T. Accounting for the multiple natures of

missing values in label-free quantitative proteomics data sets to compare imputation strategies. *J.*

Proteome Res. **15**, 1116–1125 (2016).

40. Rouder, J. N., Speckman, P. L., Sun, D., Morey, R. D. & Iverson, G. Bayesian t tests for

accepting and rejecting the null hypothesis. *Psychon. Bull. Rev.* **16**, 225–237 (2009).

41. Palasca, O., Santos, A., Stolte, C., Gorodkin, J. & Jensen, L. J. TISSUES 2.0: an integrative web

resource on mammalian tissue expression. *Database (Oxford)* **2018**, (2018).

42. Whelan, S. A. *et al.* Assessment of a 60-biomarker health surveillance panel (HSP) on whole

blood from remote sampling devices by targeted LC/MRM-MS and discovery DIA-MS analysis.

Anal. Chem. **95**, 11007–11018 (2023).

43. Beernink, R. H. J., Schuitemaker, J. H. N., Zwertbroek, E. F., Scherjon, S. A. & Cremers, T. I. F.

H. Early pregnancy biomarker discovery study for spontaneous preterm birth. *Placenta* **139**,

112–119 (2023).

44. McElrath, T. F. *et al.* Circulating microparticle proteins obtained in the late first trimester predict

spontaneous preterm birth at less than 35 weeks' gestation: a panel validation with specific

characterization by parity. *Am. J. Obstet. Gynecol.* **220**, 488.e1–488.e11 (2019).

45. Wei, C. *et al.* Identification and verification of diagnostic biomarkers in recurrent pregnancy loss

via machine learning algorithm and WGCNA. *Front. Immunol.* **14**, 1241816 (2023).

46. Wei, P. *et al.* Identification and validation of a signature based on macrophage cell marker genes

to predict recurrent miscarriage by integrated analysis of single-cell and bulk RNA-sequencing.

Front. Immunol. **13**, 1053819 (2022).

47. Yin, X.-J., Hong, W., Tian, F.-J. & Li, X.-C. Proteomic analysis of decidua in patients with

recurrent pregnancy loss (RPL) reveals mitochondrial oxidative stress dysfunction. *Clin.*

Proteomics **18**, 9 (2021).

48. Qiu, Q. *et al.* Significance of IGFBP-4 in the development of fetal growth restriction. *J. Clin.*

Endocrinol. Metab. **97**, E1429–39 (2012).

49. Zhang, T., Du, T., Li, W., Yang, S. & Liang, W. Sex hormone-binding globulin levels during the

first trimester may predict gestational diabetes mellitus development. *Biomark. Med.* **12**, 239–

244 (2018).

50. Hedderson, M. M. *et al.* Prepregnancy SHBG concentrations and risk for subsequently

developing gestational diabetes mellitus. *Diabetes Care* **37**, 1296–1303 (2014).

51. Van Ostade, X., Dom, M., Tjalma, W. & Van Raemdonck, G. Candidate biomarkers in the

cervical vaginal fluid for the (self-)diagnosis of cervical precancer. *Arch. Gynecol. Obstet.* **297**,

295–311 (2018).

52. Starodubtseva, N. L. *et al.* Label-free cervicovaginal fluid proteome profiling reflects the cervix

neoplastic transformation. *J. Mass Spectrom.* **54**, 693–703 (2019).

53. Mukherjee, A. *et al.* Insights on proteomics-driven body fluid-based biomarkers of cervical

cancer. *Proteomes* **10**, 13 (2022).

54. Van Raemdonck, G. A. A., Tjalma, W. A. A., Coen, E. P., Depuydt, C. E. & Van Ostade, X. W.

M. Identification of protein biomarkers for cervical cancer using human cervicovaginal fluid.

PLoS One **9**, e106488 (2014).

55. Olalekan, S., Xie, B., Back, R., Eckart, H. & Basu, A. Characterizing the tumor

microenvironment of metastatic ovarian cancer by single-cell transcriptomics. *Cell Rep.* **35**,

109165 (2021).

56. Qian, L. *et al.* Proteomic landscape of epithelial ovarian cancer. *Nat. Commun.* **15**, 6462 (2024).

57. Whitwell, H. J. *et al.* Improved early detection of ovarian cancer using longitudinal multimarker

models. *Br. J. Cancer* **122**, 847–856 (2020).

58. Radu, M. R. *et al.* Ovarian cancer: Biomarkers and targeted therapy. *Biomedicines* **9**, 693 (2021).

59. Atallah, G. A., Abd Aziz, N. H., Teik, C. K., Shafiee, M. N. & Kampan, N. C. New predictive

biomarkers for ovarian cancer. *Diagnostics (Basel)* **11**, 465 (2021).

60. Lupia, M. *et al.* CD73 regulates stemness and epithelial-mesenchymal transition in ovarian

cancer-initiating cells. *Stem Cell Reports* **10**, 1412–1425 (2018).

61. Kim, H. *et al.* Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in

ovarian cancer. *Br. J. Cancer* **84**, 643–650 (2001).

62. Gipson, I. K. *et al.* Mucin genes expressed by human female reproductive tract epithelia. *Biol.*

Reprod. **56**, 999–1011 (1997).

63. Moncla, B. J., Chappell, C. A., Debo, B. M. & Meyn, L. A. The effects of hormones and vaginal

microflora on the glycome of the female genital tract: Cervical-vaginal fluid. *PLoS One* **11**,

e0158687 (2016).

64. Njoku, K., Chiasserini, D., Whetton, A. D. & Crosbie, E. J. Proteomic biomarkers for the

detection of endometrial cancer. *Cancers (Basel)* **11**, 1572 (2019).

65. Coll-de la Rubia, E. *et al.* Prognostic biomarkers in endometrial cancer: A systematic review and

meta-analysis. *J. Clin. Med.* **9**, 1900 (2020).

66. Degez, M. *et al.* Endometrial cancer: A systematic review of HE4, REM and REM-B. *Clin.*

Chim. Acta **515**, 27–36 (2021).

67. Romano, A. *et al.* Endometrial cancer diagnostic and prognostic algorithms based on proteomics,

metabolomics, and clinical data: a systematic review. *Front. Oncol.* **13**, 1120178 (2023).

68. Martinez-Garcia, E. *et al.* Targeted proteomics identifies proteomic signatures in liquid biopsies

of the endometrium to diagnose endometrial cancer and assist in the prediction of the optimal

surgical treatment. *Clin. Cancer Res.* **23**, 6458–6467 (2017).

69. Njoku, K. *et al.* Quantitative SWATH-based proteomic profiling of urine for the identification of

endometrial cancer biomarkers in symptomatic women. *Br. J. Cancer* **128**, 1723–1732 (2023).

70. Mirza, Z. & Abdel-Dayem, U. A. Uncovering potential roles of differentially expressed genes,

upstream regulators, and canonical pathways in endometriosis using an in silico genomics

approach. *Diagnostics (Basel)* **10**, 416 (2020).

71. Yang, H., Kang, K., Cheng, C., Mamillapalli, R. & Taylor, H. S. Integrative analysis reveals

regulatory programs in endometriosis. *Reprod. Sci.* **22**, 1060–1072 (2015).

72. Azeze, G. G. *et al.* Proteomics approach to discovering non-invasive diagnostic biomarkers and

understanding the pathogenesis of endometriosis: a systematic review and meta-analysis. *J.*

Transl. Med. **22**, 685 (2024).

73. Méar, L. *et al.* The eutopic endometrium proteome in endometriosis reveals candidate markers

and molecular mechanisms of physiopathology. *Diagnostics (Basel)* **12**, 419 (2022).

74. Janša, V. *et al.* Proteomic analysis of peritoneal fluid identified COMP and TGFBI as new

candidate biomarkers for endometriosis. *Sci. Rep.* **11**, 20870 (2021).

75. Anastasiu, C. V. *et al.* Biomarkers for the noninvasive diagnosis of endometriosis: State of the

art and future perspectives. *Int. J. Mol. Sci.* **21**, 1750 (2020).

76. Irungu, S. *et al.* Discovery of non-invasive biomarkers for the diagnosis of endometriosis. *Clin.*

Proteomics **16**, 14 (2019).

77. Ludwig, C. *et al.* Data-independent acquisition-based SWATH-MS for quantitative proteomics: a

tutorial. *Mol. Syst. Biol.* **14**, e8126 (2018).

78. Gérard, N., Caillaud, M., Martoriati, A., Goudet, G. & Lalmanach, A.-C. The interleukin-1

system and female reproduction. *J. Endocrinol.* **180**, 203–212 (2004).

79. Zubor, P. *et al.* Rho GTPases in gynecologic cancers: In-depth analysis toward the paradigm

change from reactive to predictive, preventive, and personalized medical approach benefiting the

patient and healthcare. *Cancers (Basel)* **12**, 1292 (2020).

80. Kanaka, V., Drakakis, P., Loutradis, D. & Tsangaris, G. T. Proteomics in the study of female

fertility: an update. *Expert Rev. Proteomics* **20**, 319–330 (2023).

81. Raykov, T. & Marcoulides, G. A. On desirability of parsimony in structural equation model

selection. *Struct. Equ. Modeling* **6**, 292–300 (1999).